Graphene Oxide Noncovalent Photosensitizer and Its Anticancer Activity In Vitro

Graphene oxide (GO) was investigated as a potential drug‐delivery system due to its special properties and biocompatibility. Thus far, little has been done to use GO as a photosensitive drug‐delivery system and to explore its anticancer activity in vitro in photodynamic therapy applications. Here, a novel GO–hypocrellin A (GO‐HA) hybrid was prepared by a simple noncovalent method and its photodynamic activity was studied for the first time. The results showed that an efficient loading amount of HA on GO was as high as 1.0 mg mg−1 and the stability of the hybrid was superior to that of the free hypocrellin A in aqueous solution. Furthermore, GO‐HA can be excited by irradiation with light of appropriate wavelength to generate singlet oxygen, and in vitro experiments illustrated that GO‐HA was efficiently taken up by tumor cells, and that light irradiation of such impregnated cells resulted in significant cell death. Thus, these properties of GO‐HA could possibly make it especially promising for use in clinical photodynamic therapy. Delivery service: A hybrid of functionalized graphene oxide (GO) and hypocrellin A (HA) has been prepared (see picture) and exploited as a drug‐delivery system of HA. The complex has obvious photodynamic activity in vitro: cell and nuclear morphological changes in impregnated tumor cells were observed upon irradiation by light.